Modality
ADC
MOA
KIF18Ai
Target
FLT3
Pathway
Hedgehog
MMADPKDWilms
Development Pipeline
Preclinical
Aug 2019
→ Jul 2031
PreclinicalCurrent
NCT04838353
2,460 pts·ADPKD
2019-08→2027-05·Active
NCT05755860
1,029 pts·ADPKD
2025-07→2031-07·Recruiting
3,489 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-11-204mo agoAdCom· Wilms
2027-05-021.1y awayInterim· ADPKD
2031-07-135.3y awayInterim· ADPKD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Active
Preclinical
Recruit…
Catalysts
AdCom
2025-11-20 · 4mo ago
Wilms
Interim
2027-05-02 · 1.1y away
ADPKD
Interim
2031-07-13 · 5.3y away
ADPKD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04838353 | Preclinical | ADPKD | Active | 2460 | EDSS |
| NCT05755860 | Preclinical | ADPKD | Recruiting | 1029 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 |